Bupa has become the first major private medical insurer to provide preventive healthcare for all customers, addressing serious conditions before symptoms appear.
The new ‘Prevention Pathways’ target breast cancer, cardiovascular disease, and diabetes, guiding customers based on clinical assessments, genetic risk, and lifestyle factors. By 2027, over 200,000 Bupa customers are expected to benefit.
Customers gain end-to-end care, from DNA testing and genetic counselling to GP appointments, expert support, lifestyle advice, and risk-reducing interventions — including potentially life-saving surgeries.
The programme is powered by Bupa’s AI-driven Blua digital service, which helps individuals understand health risks and take preventive action.
Breast cancer pathway example: Digital triage and genetic testing identify customers at high risk, offering options such as preventive medication or mastectomy, expected to benefit 36,000 people by 2027.
High-risk cardiovascular and diabetes patients can access Bupa’s Weight Management service.
Bupa describes the programme as a shift from reactive treatment to personalised prevention, marking a new era in healthcare delivery.
Dan Sullivan, Product and Proposition Director for Bupa Insurance, said: “Today marks a significant milestone as Bupa becomes the first major private medical insurer to offer fully integrated, genomics-led personalised and preventive healthcare as part of its standard cover.
“By moving from treating illness, to predicting and preventing it, we are redefining the role of healthcare.
“Early intervention leads to better outcomes, so being able to prevent illness before reaching crisis stage is key. This shift allows us to provide personal treatment plans for everyone and support our customers better than ever before.”
Bupa is also integrating Bupa Medication Check for all UK customers taking regular medication, directing potentially 4.2m customers onto the right medication for their genetic profile for the first time.
This personalised product uses a simple saliva test to determine which medications are most likely to be effective or cause side effects, helping people to get the right medication, at the right dose, first time.
This is a shift from the “trial and error” approach to prescribing medication, particularly for chronic conditions, improving long-term patient outcomes.
Dr Rebecca Rohrer, Clinical Innovation and Genomics Director for Bupa, said: “This is a turning point in how we think about healthcare, enabling people to be more proactive in preventing or delaying ill-health and having faster access to medication that works for them.
“Genomics truly is at the frontier of healthcare, and by harnessing the learnings from our pilot study of over 12,000 customers we’re uniquely placed to offer personalised care to each individual customer, for the best personalised health outcome.”
The Medication Check pathway will be available to Bupa UK Insurance customers from 1 June. The breast cancer, diabetes and cardiovascular disease pathways will be available to Bupa UK Insurance customers from 1 September.
Leave a Comment